Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ardelyx, Inc. (NASDAQ: ARDX) announced a conference call to discuss its first quarter financial results and provide a business update on May 3, 2023, at 4:30 p.m. ET. The call can be accessed by dialing (844) 481-2838 domestically or (412) 317-1858 internationally, with a live audio webcast available on the company’s website. Ardelyx is committed to developing first-in-class medicines for unmet medical needs, having achieved success with its approved product IBSRELA® (tenapanor). Additionally, the company is advancing XPHOZAH® for chronic kidney disease patients and has multiple collaborations in place with international partners for the commercialization of tenapanor. More details can be found on Ardelyx's website.
Ardelyx, Inc. (Nasdaq: ARDX) has announced the resubmission of a New Drug Application (NDA) for XPHOZAH (tenapanor) targeting serum phosphate control in adults with chronic kidney disease (CKD) on dialysis. This NDA supports over 1,200 patients' data from three successful Phase 3 trials and two Phase 4 trials, all meeting critical endpoints. Confirmation of the resubmission's completeness from the FDA is anticipated by mid-May. XPHOZAH functions as a phosphate absorption inhibitor, requiring a simple dosing regimen of one 30mg tablet twice daily. Hyperphosphatemia, affecting many CKD patients, underscores the drug's potential significance. Ardelyx continues to pursue innovative treatments for unmet medical needs.
Ardelyx, Inc. (Nasdaq: ARDX) announced on April 10, 2023, that its compensation committee granted stock options and Restricted Stock Units (RSUs) to seven new non-executive employees. A total of 238,426 shares in stock options and 89,250 RSUs were awarded, with the exercise price set at $4.26 per share, corresponding to the company's closing stock price on the grant date. The stock options will vest over four years, while the RSUs will also vest over the same period, with varying percentages vesting at specified intervals. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and is intended to incentivize new employees.
Ardelyx is focused on developing innovative medicines, including its FDA-approved product IBSRELA and ongoing studies for its candidates targeting kidney-related health issues.